CN105722504A - 无定形的镁取代磷酸钙组合物及其用途 - Google Patents

无定形的镁取代磷酸钙组合物及其用途 Download PDF

Info

Publication number
CN105722504A
CN105722504A CN201480060734.7A CN201480060734A CN105722504A CN 105722504 A CN105722504 A CN 105722504A CN 201480060734 A CN201480060734 A CN 201480060734A CN 105722504 A CN105722504 A CN 105722504A
Authority
CN
China
Prior art keywords
composition
treatment
calcium phosphate
cargo
amorphous magnesium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480060734.7A
Other languages
English (en)
Chinese (zh)
Inventor
乔纳森·约瑟夫·鲍威尔
努诺·若热·罗德里格斯·法里亚
拉埃蒂蒂亚·佩莱
拉谢尔·埃维特
艾玛·托马斯-麦凯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
British Research And Innovation Agency
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of CN105722504A publication Critical patent/CN105722504A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B25/00—Phosphorus; Compounds thereof
    • C01B25/16—Oxyacids of phosphorus; Salts thereof
    • C01B25/26—Phosphates
    • C01B25/32—Phosphates of magnesium, calcium, strontium, or barium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587—Nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Optics & Photonics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
CN201480060734.7A 2013-11-05 2014-11-05 无定形的镁取代磷酸钙组合物及其用途 Pending CN105722504A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1319548.2 2013-11-05
GBGB1319548.2A GB201319548D0 (en) 2013-11-05 2013-11-05 Amorphous magnesium-substituted calcium phosphate compositions and their uses
PCT/GB2014/053291 WO2015067939A1 (en) 2013-11-05 2014-11-05 Amorphous magnesium-substituted calcium phosphate compositions and their uses

Publications (1)

Publication Number Publication Date
CN105722504A true CN105722504A (zh) 2016-06-29

Family

ID=49767709

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480060734.7A Pending CN105722504A (zh) 2013-11-05 2014-11-05 无定形的镁取代磷酸钙组合物及其用途

Country Status (16)

Country Link
US (1) US10596122B2 (cg-RX-API-DMAC7.html)
EP (1) EP3065715B1 (cg-RX-API-DMAC7.html)
JP (2) JP2016537408A (cg-RX-API-DMAC7.html)
KR (1) KR20160079060A (cg-RX-API-DMAC7.html)
CN (1) CN105722504A (cg-RX-API-DMAC7.html)
AU (1) AU2014345334B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016009809A2 (cg-RX-API-DMAC7.html)
CA (1) CA2929123A1 (cg-RX-API-DMAC7.html)
EA (1) EA201690659A1 (cg-RX-API-DMAC7.html)
ES (1) ES2761559T3 (cg-RX-API-DMAC7.html)
GB (1) GB201319548D0 (cg-RX-API-DMAC7.html)
IL (1) IL245380B (cg-RX-API-DMAC7.html)
MX (1) MX367473B (cg-RX-API-DMAC7.html)
SG (2) SG10201803562YA (cg-RX-API-DMAC7.html)
WO (1) WO2015067939A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201602906B (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110573455A (zh) * 2017-04-27 2019-12-13 武礼伟仁株式会社 羟基磷灰石、化妆品和食品及其生产方法
CN111417459A (zh) * 2019-07-05 2020-07-14 广州中大医疗器械有限公司 一种新型可载药微球及其制备方法
CN116768175A (zh) * 2023-07-01 2023-09-19 常州市第二人民医院 高稳定性生物活性无定形磷酸钙镁的制备方法及应用
CN118929595A (zh) * 2024-08-30 2024-11-12 昆明理工大学 稳定型掺镁无定形磷酸钙纳米颗粒的制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201319548D0 (en) 2013-11-05 2013-12-18 Medical Res Council Amorphous magnesium-substituted calcium phosphate compositions and their uses
FR3021045B1 (fr) * 2014-05-16 2020-02-21 Solvay Sa Procede de production d'un reactif phosphocalcique, reactif obtenu et son utilisation
KR101893110B1 (ko) * 2016-07-27 2018-08-31 삼일제약 주식회사 비페닐디메틸디카르복실레이트 및 마늘유를 포함하는 제제
EP3538659A4 (en) * 2016-11-09 2020-07-15 Engene, Inc. INTESTINAL EXPRESSION OF THE SCHEDULED DEATH LIGAND 1
WO2021086252A1 (en) 2019-10-30 2021-05-06 Psilox Ab Stabilized amorphous calcium magnesium phosphate particle compositions
KR20260019884A (ko) * 2024-08-02 2026-02-10 한국과학기술연구원 레이저를 이용한 아파타이트 분말 연속 합성 장치 및 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541037B1 (en) * 1995-05-19 2003-04-01 Etex Corporation Delivery vehicle
CN102014880A (zh) * 2008-05-01 2011-04-13 Nod药物公司 治疗性磷酸钙颗粒及其制备和使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
EP1872798B1 (en) 2005-04-06 2013-06-05 Kabushiki Kaisha Sangi Intestinal absorptive anti-tumor agent
EP2106217B1 (en) 2006-12-12 2019-03-13 Firmenich S.A. Active ingredient delivery system with an amorphous metal salt as carrier
GB201319548D0 (en) 2013-11-05 2013-12-18 Medical Res Council Amorphous magnesium-substituted calcium phosphate compositions and their uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541037B1 (en) * 1995-05-19 2003-04-01 Etex Corporation Delivery vehicle
CN102014880A (zh) * 2008-05-01 2011-04-13 Nod药物公司 治疗性磷酸钙颗粒及其制备和使用方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DONGHYUN LEE,ET AL: "Chemical synthesis and characterization of magnesium substituted amorphous calcium phosphate (MG-ACP)", 《MATERIALS SCIENCE AND ENGINEERING C》 *
FENG CHEN,ET AL: "Europium-doped amorphous calcium phosphate porous nanospheres: preparation and application as luminescent drug carriers", 《NANOSCALE RESEARCH LETTERS》 *
N.C.BLUMENTHAL,ET AL: "Stabilization of Amorphous Calcium Phosphate by Mg and ATP", 《CALCIFIED TISSUE RESEARCH》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110573455A (zh) * 2017-04-27 2019-12-13 武礼伟仁株式会社 羟基磷灰石、化妆品和食品及其生产方法
CN116947003A (zh) * 2017-04-27 2023-10-27 武礼伟仁株式会社 羟基磷灰石、化妆品和食品及其生产方法
US12201709B2 (en) 2017-04-27 2025-01-21 Brainy Inc. Hydroxyapatite, cosmetic, food, and method for producing the same
CN111417459A (zh) * 2019-07-05 2020-07-14 广州中大医疗器械有限公司 一种新型可载药微球及其制备方法
CN116768175A (zh) * 2023-07-01 2023-09-19 常州市第二人民医院 高稳定性生物活性无定形磷酸钙镁的制备方法及应用
CN118929595A (zh) * 2024-08-30 2024-11-12 昆明理工大学 稳定型掺镁无定形磷酸钙纳米颗粒的制备方法

Also Published As

Publication number Publication date
US10596122B2 (en) 2020-03-24
MX2016005415A (es) 2017-03-01
AU2014345334B2 (en) 2019-10-31
ZA201602906B (en) 2019-09-25
EA201690659A1 (ru) 2016-10-31
MX367473B (es) 2019-08-23
IL245380A0 (en) 2016-06-30
WO2015067939A1 (en) 2015-05-14
ES2761559T3 (es) 2020-05-20
US20160235683A1 (en) 2016-08-18
GB201319548D0 (en) 2013-12-18
IL245380B (en) 2019-02-28
KR20160079060A (ko) 2016-07-05
EP3065715B1 (en) 2019-10-02
AU2014345334A1 (en) 2016-05-19
JP2016537408A (ja) 2016-12-01
BR112016009809A2 (pt) 2017-12-05
EP3065715A1 (en) 2016-09-14
JP2020073467A (ja) 2020-05-14
CA2929123A1 (en) 2015-05-14
SG11201603261PA (en) 2016-05-30
SG10201803562YA (en) 2018-06-28

Similar Documents

Publication Publication Date Title
EP3065715B1 (en) Amorphous magnesium-substituted calcium phosphate compositions and their uses
Li et al. Orally administrated hydrogel harnessing intratumoral microbiome and microbiota-related immune responses for potentiated colorectal cancer treatment
JP6570082B2 (ja) 炎症を治療するための方法および組成物
ES2730273T3 (es) Métodos y composiciones para inmunoterapia sostenida
ES3029611T3 (en) Metabolites for treatment and prevention of autoimmune disease
EP3154521B1 (en) Disintegratable core/shell silica particles for encapsulating and releasing bioactive macromolecules
WO2020136657A1 (en) Polymeric nanovaccines and uses thereof
Deng et al. Tea polyphenol liposomes overcome gastric mucus to treat Helicobacter pylori infection and enhance the intestinal microenvironment
JP2016537408A5 (cg-RX-API-DMAC7.html)
Jiang et al. PEG-grafted arsenic trioxide-loaded mesoporous silica nanoparticles endowed with pH-triggered delivery for liver cancer therapy
CN119524154B (zh) 一种基于减毒细菌外膜囊泡且可实现siRNA和阿霉素共递送的纳米平台及其制备方法
KR20170104024A (ko) 헬리코박터파일로리균 유래 나노소포 및 이의 용도
Sun et al. Oral microbiota-responsive ZIF nanoplatform via double-layer glycans modified combined with PD-1 inhibitor for treatment of microsatellite-stable colorectal cancer
CN116966148B (zh) 一种膜融合脂质体、其构建的多功能巨噬细胞及肿瘤免疫治疗应用
CN117940137A (zh) 人工酶-细菌系统及其用途
Nayak et al. Chitosan micro and nanoparticles for delivery of drugs and therapeutic proteins
CN109432050A (zh) 一种自然杀伤细胞外泌体和大分子树枝状聚合物的组合物
Cordeiro Impact of microbiome in cancer nano-immunotherapy
Shi et al. Bioactive nanoparticles for boosting tumor immunotherapy via Ca2+ interference mediate TME reprogramming and PD-L1 depletion
HK40020863A (en) Methods and compositions for treating inflammation
Italiani et al. Concepts for Nano-delivery of Therapeutic Immunomodulatory Agents
BR112014023859B1 (pt) Nanopartícula, uso da mesma, e composição
Mondalek et al. Research Inhibition of angiogenesis-and inflammation-inducing factors in human colon cancer cells in vitro and in ovo by free and nanoparticle-encapsulated redox dye, DCPIP

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20200109

Address after: UK

Applicant after: British Research and Innovation Agency

Address before: Swindon, Wiltshire, UK

Applicant before: Nat Inst For Medical Res

TA01 Transfer of patent application right
RJ01 Rejection of invention patent application after publication

Application publication date: 20160629

RJ01 Rejection of invention patent application after publication